SLC16A1 and prostate adenocarcinoma: Differential expression of SLC16A1 in urological cancers of different clinical stages was also verified by the UALCAN database, as PRAD was missing clinical stage data, but significant differences in SLC16A1 expression were also found in patients with different Gleason scores, as detailed in Figure 2.